Radioactive antibody targets tough prostate cancer in early trial
NCT ID NCT07259213
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called 161Tb-RAD402 in 73 men with castration-resistant prostate cancer, a type that has stopped responding to hormone therapy. The drug is a radioactive antibody designed to seek out and attack cancer cells by targeting a protein called free PSA. The main goals are to check safety, find the right dose, and see if it can shrink tumors or lower PSA levels.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Icon Cancer Centre Hollywood
RECRUITINGNedlands, Western Australia, 6009, Australia
-
Wollongong Hospital
RECRUITINGWollongong, New South Wales, 2500, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo tame resistant prostate cancer?
- Can a radioactive 'Smart Bomb' shrink resistant prostate tumors?
- AI could predict which prostate cancers turn aggressive
- New hope for hard-to-treat prostate cancer: drug combo trial launches
- New combo therapy aims to delay prostate cancer progression
- Prostate cancer protein map could guide future treatments